Comparison of the Effectiveness and Tolerability of Exenatide Once-weekly Compared to Basal Insulins

NCT02974244 · clinicaltrials.gov ↗

COMPLETED

Status

7000

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes

Interventions

DRUG: exenatide once weekly
DRUG: basal insulin

Sponsor

AstraZeneca